Latest News and Press Releases

The first child has been enrolled in Phase 2 INTEGUMENT-INFANT study evaluating the safety and tolerability of investigational ZORYVE cream for AD

FDA has approved the supplemental New Drug Application (sNDA) for ZORYVE® foam 0.3% for the treatment of plaque psoriasis

WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4...

Arcutis today announced the signing of a co-promotion agreement with Kowa Pharmaceuticals America, Inc.

Arcutis today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis.

Arcutis will host a KOL virtual event July 29, 2024